NEW YORK, December 29, 2025, 14:15 ET — Regular session
- Bristol Myers Squibb shares were down about 0.7% in afternoon trading, underperforming the broad market.
- Thin year-end volumes are amplifying stock moves across U.S. equities, a strategist said.
- Investors are also looking ahead to Bristol Myers’ Jan. 2 shareholder record date for its next dividend and its Feb. 5 earnings report.
Bristol Myers Squibb shares fell on Monday, with the drugmaker lagging a slightly weaker U.S. stock market in holiday-thinned trading. The stock was down 0.7% at $54.27 in afternoon trade.
The move matters now because the final week of the year often brings abrupt swings on light volume, even when company-specific headlines are scarce. Bristol Myers is also approaching two calendar catalysts that can influence positioning: its next dividend record date and its next earnings report.
U.S. stocks eased from record highs at the start of a holiday-shortened week, and markets are still digesting expectations for Federal Reserve rate cuts in 2026. “Volume is low, so any kind of activity could push the index one way or the other,” said Sam Stovall of CFRA Research. Reuters
Healthcare was steadier than more volatile pockets of the market, but Bristol Myers still slipped. The Health Care Select Sector SPDR Fund was down about 0.1%, while the SPDR S&P Biotech ETF fell about 1.2%.
Peers were mixed. Merck and Johnson & Johnson were modestly higher, while Pfizer edged lower; Eli Lilly outperformed with a gain of about 0.6%.
Traders pointed to year-end rebalancing rather than a single Bristol Myers catalyst behind the move. “Tax-loss harvesting” — selling losing positions to offset gains for tax purposes — can also reshuffle leadership in the final sessions, Stovall said. Reuters
Bristol Myers, which sells the blood thinner Eliquis and cancer therapies including Opdivo, has been a higher-yielding name within large-cap pharmaceuticals, a factor that can draw income-focused buying during bouts of market uncertainty.
On the shareholder return side, the company said earlier this month its board declared a quarterly dividend of $0.63 per share, payable Feb. 2, 2026, to shareholders of record at the close of business on Jan. 2, 2026.
The ex-dividend date — the first day the stock trades without the right to receive the next dividend — can bring short-term repositioning, particularly among income and options traders, as the calendar approaches.
The next fundamental waypoint is earnings. Bristol Myers said it will report fourth-quarter 2025 results on Feb. 5, 2026, and host a conference call at 8 a.m. ET.
Investors are expected to focus on any updates to 2026 expectations and the pace of revenue replacement in the company’s newer portfolio, as well as pipeline milestones that could shape longer-term growth assumptions.
Technically, the stock is trading well below its 52-week high of $63.33 but above its 52-week low of $42.52, levels some traders use as rough reference points for resistance and support.
For the rest of the session, traders will be watching whether year-end flows keep pressure on defensive sectors and whether broader rate-cut wagers — and upcoming Fed communications — change the tone into the final trading days of 2025.
